Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).

Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Wallach J, Halberstadt AL.

Drug Test Anal. 2019 May 13. doi: 10.1002/dta.2613. [Epub ahead of print]

PMID:
31083768
2.

Syntheses and analytical characterizations of the research chemical 1-[1-(2-fluorophenyl)-2-phenylethyl]pyrrolidine (fluorolintane) and five of its isomers.

Dybek M, Wallach J, Kavanagh PV, Colestock T, Filbman N, Dowling G, Westphal F, Elliott SP, Adejare A, Brandt SD.

Drug Test Anal. 2019 Apr 29. doi: 10.1002/dta.2608. [Epub ahead of print]

PMID:
31033229
3.

Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864).

Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V.

Drug Test Anal. 2019 Mar;11(3):541-549. doi: 10.1002/dta.2561. Epub 2019 Feb 5.

PMID:
30578721
4.

Improving the reliability of the iron concentration quantification for iron oxide nanoparticle suspensions: a two-institutions study.

Costo R, Heinke D, Grüttner C, Westphal F, Morales MP, Veintemillas-Verdaguer S, Gehrke N.

Anal Bioanal Chem. 2019 Mar;411(9):1895-1903. doi: 10.1007/s00216-018-1463-2. Epub 2018 Nov 12.

5.

SPECT/CT in Postoperative Foot and Ankle Pain.

Kampen WU, Westphal F, Van den Wyngaert T, Strobel K, Kuwert T, Van der Bruggen W, Gnanasegaran G, Jens JH, Paycha F.

Semin Nucl Med. 2018 Sep;48(5):454-468. doi: 10.1053/j.semnuclmed.2018.03.003. Epub 2018 Apr 18. Review.

PMID:
30193651
6.
7.

Therapeutic options in advanced heart failure.

Bekfani T, Westphal F, Schulze PC.

Clin Res Cardiol. 2018 Aug;107(Suppl 2):114-119. doi: 10.1007/s00392-018-1318-z. Epub 2018 Jul 9. No abstract available.

PMID:
29987596
8.

BUNDLE OF MEASURES TO SUPPORT INTRAHOSPITAL EXCLUSIVE BREASTFEEDING: EVIDENCE OF SYSTEMATIC REVIEWS.

Coca KP, Pinto VL, Westphal F, Mania PNA, Abrão ACFV.

Rev Paul Pediatr. 2018 Apr-Jun;36(2):214-220. doi: 10.1590/1984-0462/;2018;36;2;00002. Epub 2018 Apr 23. Portuguese, English.

9.

Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers.

McLaughlin G, Baumann MH, Kavanagh PV, Morris N, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Westphal F, Walther D, Brandt SD.

Drug Test Anal. 2018 Sep;10(9):1404-1416. doi: 10.1002/dta.2396. Epub 2018 May 23.

PMID:
29673128
10.

Physical characterization and in vivo organ distribution of coated iron oxide nanoparticles.

Sharma A, Cornejo C, Mihalic J, Geyh A, Bordelon DE, Korangath P, Westphal F, Gruettner C, Ivkov R.

Sci Rep. 2018 Mar 20;8(1):4916. doi: 10.1038/s41598-018-23317-2.

12.

Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE.

Angerer V, Mogler L, Steitz JP, Bisel P, Hess C, Schoeder CT, Müller CE, Huppertz LM, Westphal F, Schäper J, Auwärter V.

Drug Test Anal. 2018 Mar;10(3):597-603. doi: 10.1002/dta.2237. Epub 2017 Aug 9.

PMID:
28670781
13.

Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).

Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL.

Drug Test Anal. 2018 Feb;10(2):310-322. doi: 10.1002/dta.2222. Epub 2017 Jul 27.

14.

Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues.

Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, Westphal F, Brandt SD, Adejare A.

Drug Test Anal. 2018 Feb;10(2):272-283. doi: 10.1002/dta.2213. Epub 2017 Jul 26.

PMID:
28513099
15.

Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD).

Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, Nichols DE, Halberstadt AL.

Drug Test Anal. 2017 Oct;9(10):1641-1649. doi: 10.1002/dta.2196. Epub 2017 May 10.

16.

Analysis of six 'neuro-enhancing' phenidate analogs.

Klare H, Neudörfl JM, Brandt SD, Mischler E, Meier-Giebing S, Deluweit K, Westphal F, Laussmann T.

Drug Test Anal. 2017 Mar;9(3):423-435. doi: 10.1002/dta.2161.

PMID:
28067464
17.

Association of gestational age with the option of pregnancy termination for fetal abnormalities incompatible with neonatal survival.

Westphal F, Fustinoni SM, Pinto VL, Melo PS, Abrahão AR.

Einstein (Sao Paulo). 2016 Jul-Sep;14(3):311-316. doi: 10.1590/S1679-45082016AO3721. English, Portuguese.

18.

Stem cell labeling with iron oxide nanoparticles: impact of 3D culture on cell labeling maintenance.

Kilian T, Fidler F, Kasten A, Nietzer S, Landgraf V, Weiß K, Walles H, Westphal F, Hackenberg S, Grüttner C, Steinke M.

Nanomedicine (Lond). 2016 Aug;11(15):1957-70. doi: 10.2217/nnm-2016-0042. Epub 2016 Jul 26.

PMID:
27456272
19.

Separation and structural characterization of the new synthetic cannabinoid JWH-018 cyclohexyl methyl derivative "NE-CHMIMO" using flash chromatography, GC-MS, IR and NMR spectroscopy.

Angerer V, Bisel P, Moosmann B, Westphal F, Auwärter V.

Forensic Sci Int. 2016 Sep;266:e93-e98. doi: 10.1016/j.forsciint.2016.05.031. Epub 2016 Jun 3.

PMID:
27297324
20.

Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).

Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt AL.

Drug Test Anal. 2017 Jan;9(1):38-50. doi: 10.1002/dta.1985. Epub 2016 Jun 6.

Supplemental Content

Loading ...
Support Center